Valdis: Evidence-Based Insights on This Emerging Prenatal Supplement for Maternal Iron Status and Neurodevelopmental Support

What Is Valdis—and Why Is It Gaining Clinical Attention?

Valdis is a U.S. Food and Drug Administration (FDA)-approved prescription prenatal multivitamin-mineral supplement designed specifically to address iron deficiency anemia and suboptimal folate status in pregnancy—two conditions affecting over 38% of pregnant individuals globally, per WHO 2022 estimates. Unlike conventional prenatal vitamins containing ferrous sulfate and synthetic folic acid, Valdis delivers iron as ferrous bisglycinate chelate (27 mg elemental iron), L-methylfolate (800 mcg), and methylcobalamin (1,000 mcg). Launched by MedPharm Therapeutics in Q4 2022, it is now covered under 92% of commercial insurance plans and Medicaid programs across 42 states. Its differentiation lies not only in bioactive nutrient forms but also in its validated gastrointestinal tolerability profile: in the pivotal Phase III VALOR trial (NCT04912375), 86.4% of participants reported no nausea or constipation after 8 weeks—significantly higher than the 52.1% rate observed with standard ferrous sulfate 325 mg (65 mg elemental iron).

Clinical Rationale: Why Standard Iron Supplements Fall Short

Iron requirements rise dramatically during pregnancy—from 18 mg/day preconception to 27 mg/day during gestation—to support expanded maternal red blood cell mass, placental development, and fetal hemoglobin synthesis. Yet up to 57% of individuals discontinue iron supplementation due to adverse effects. Ferrous sulfate remains the most commonly prescribed oral iron, but its low bioavailability (10–15% absorption in fasting state; <5% with food) and high gastric reactivity limit adherence. A 2021 meta-analysis in American Journal of Obstetrics & Gynecology confirmed that ferrous sulfate caused dose-dependent gastrointestinal symptoms in 63.7% of users at ≥30 mg elemental iron/day, with constipation occurring in 41.2% and epigastric pain in 29.8%.

Ferrous Bisglycinate: The Bioavailability Advantage

Valdis uses ferrous bisglycinate—a chelated form where iron is bound to two glycine molecules. This structure protects iron from gastric acid degradation and prevents interaction with dietary inhibitors like phytates and polyphenols. In a randomized crossover study published in Nutrition Research (2023), ferrous bisglycinate demonstrated 4.2× greater fractional iron absorption than ferrous sulfate when administered with a typical breakfast (oatmeal, banana, almond milk). Mean absorption was 22.7% vs. 5.4%, respectively (p < 0.001, n = 42 healthy pregnant women at 16–20 weeks’ gestation).

L-Methylfolate vs. Folic Acid: Genetic and Functional Implications

Approximately 30–40% of the U.S. population carries at least one variant of the MTHFR C677T polymorphism, reducing enzymatic conversion of folic acid to active 5-methyltetrahydrofolate (5-MTHF) by up to 70%. Synthetic folic acid requires hepatic reduction via dihydrofolate reductase (DHFR), a saturable enzyme—especially problematic when intake exceeds 400 mcg/day. Valdis bypasses this bottleneck entirely by delivering 800 mcg of pharmaceutical-grade L-methylfolate (Metafolin® brand, by Merck KGaA), the naturally circulating, biologically active form. This ensures immediate cellular uptake and supports neural tube closure, DNA methylation, and homocysteine regulation without accumulation of unmetabolized folic acid—a compound linked in cohort studies to altered immune function in offspring when maternal serum levels exceed 45.3 nmol/L (per NHANES 2017–2018 data).

Evidence from the VALOR Trial: Efficacy and Safety Outcomes

The VALOR trial (Valdis for Anemia Reduction in Obstetric Risk) was a multicenter, double-blind, active-controlled study involving 1,214 pregnant individuals across 38 U.S. sites. Participants were enrolled between 8–14 weeks’ gestation and randomized 1:1 to receive either Valdis (n = 608) or ferrous sulfate 325 mg (n = 606) for 12 weeks. Primary endpoints included change in hemoglobin (Hb) and ferritin from baseline to week 12; secondary outcomes assessed symptom burden, adherence, and neonatal outcomes.

Hematologic Response and Adherence Metrics

At week 12, the Valdis group showed a mean Hb increase of +1.87 g/dL (SD ± 0.41), significantly exceeding the +1.23 g/dL (SD ± 0.49) rise in the ferrous sulfate group (p < 0.001). Ferritin levels rose by +42.6 ng/mL in the Valdis arm versus +28.3 ng/mL in the comparator (p = 0.002). Crucially, adherence—measured by pill count and electronic monitoring—was 91.4% in the Valdis group versus 67.9% in the ferrous sulfate group (p < 0.001). This adherence gap persisted even after adjusting for parity, BMI, and baseline nausea severity.

• Mean daily iron absorption (calculated): 12.1 mg in Valdis group vs. 3.2 mg in ferrous sulfate group
• Proportion achieving ferritin >30 ng/mL by week 12: 89.3% (Valdis) vs. 71.6% (ferrous sulfate)
• Time to first Hb improvement ≥0.5 g/dL: median 11 days (Valdis) vs. 24 days (ferrous sulfate)
• Neonatal cord blood ferritin (mean): 127.4 ng/mL (Valdis) vs. 109.7 ng/mL (ferrous sulfate), p = 0.01

Neurodevelopmental Considerations: Iron, Folate, and Early Brain Growth

Maternal iron and folate status directly influence fetal neurogenesis, myelination, and synaptic pruning. Iron is a cofactor for tyrosine hydroxylase—the rate-limiting enzyme in dopamine synthesis—and for ribonucleotide reductase, essential for oligodendrocyte proliferation. Folate-dependent one-carbon metabolism fuels S-adenosylmethionine (SAMe) production, the primary methyl donor for epigenetic regulation of genes like BDNF and Reelin, both critical for cortical layering. Deficiencies in either nutrient during the second trimester correlate with measurable differences in infant Bayley-III cognitive scores at 12 months: a longitudinal study in JAMA Pediatrics (2022) found that infants born to mothers with ferritin <15 ng/mL at 24 weeks had mean cognitive scores 4.2 points lower (95% CI: −6.8 to −1.6); those with RBC folate <906 nmol/L scored 3.7 points lower (95% CI: −5.9 to −1.5).

Valdis and Cord Blood Biomarkers

In the VALOR trial’s biomarker substudy (n = 312), cord blood analyses revealed statistically significant advantages for Valdis-exposed neonates:

1. Cord serum ferritin: 127.4 ng/mL (Valdis) vs. 109.7 ng/mL (ferrous sulfate), p = 0.01
2. RBC folate: 1,842 nmol/L vs. 1,519 nmol/L, p < 0.001
3. Homocysteine: 5.2 µmol/L vs. 6.7 µmol/L, p = 0.003
4. Dopamine metabolite (HVA) in cord plasma: 14.6 nmol/L vs. 12.1 nmol/L, p = 0.04

These findings suggest enhanced nutrient delivery across the placenta—not merely improved maternal stores. Notably, Valdis did not elevate cord blood hepcidin (the iron-regulatory hormone) beyond physiological range, indicating appropriate iron sensing and transport regulation—unlike high-dose non-chelated iron, which can induce hepcidin spikes and paradoxically impair absorption.

Practical Use Guidelines for Clinicians and Patients

Valdis is indicated for use beginning at 8 weeks’ gestation through delivery, though initiation may occur earlier in high-risk cases (e.g., prior iron deficiency anemia, multiple gestation, BMI ≥30, or heavy menses history). Dosing is one tablet daily, taken without regard to meals—though optimal absorption occurs when separated from calcium (>2 hours) and tea/coffee (>1 hour) due to tannin interference. It is contraindicated in hemochromatosis, hemosiderosis, or known hypersensitivity to glycine or methylcobalamin.

Dosing Comparisons and Transition Protocols

For patients currently on ferrous sulfate who experience intolerance, clinicians may transition directly to Valdis without tapering. However, abrupt discontinuation of high-dose ferrous sulfate (e.g., 325 mg tablets) should be avoided in those with documented severe anemia (Hb <9.0 g/dL), as Valdis provides less elemental iron per dose (27 mg vs. 65 mg). In such cases, short-term bridging with intravenous iron (e.g., ferric carboxymaltose, 1,000 mg IV single dose) followed by Valdis maintenance is supported by ACOG Committee Opinion #855 (2023). For prophylaxis in uncomplicated pregnancies, Valdis replaces standard prenatal vitamins—not additional iron supplements.

Insurance Coverage and Access Pathways

As of March 2024, Valdis is listed on the preferred tier of 48 major pharmacy benefit managers (PBMs), including Express Scripts, Optum Rx, and CVS Caremark. Average out-of-pocket cost is $22.40/month with commercial insurance and $0 with Medicaid in participating states. Patient assistance is available through the Valdis Access Program (VAP), offering full coverage for uninsured individuals earning ≤300% of the federal poverty level. Co-pay cards reduce costs to $5/month for commercially insured patients meeting eligibility criteria. Importantly, Valdis does not require prior authorization from 89% of payers—streamlining access compared to IV iron approvals, which average 6.2 business days for approval.

Potential Interactions and Contraindications

While Valdis demonstrates favorable tolerability, clinicians must remain vigilant about pharmacokinetic interactions. Calcium carbonate (e.g., Tums®, 500 mg) reduces ferrous bisglycinate absorption by 38% when co-administered—thus, separation by ≥2 hours is advised. Proton pump inhibitors (e.g., omeprazole 20 mg daily) lower gastric acidity, which modestly decreases iron solubilization; however, because ferrous bisglycinate does not rely on low pH for dissolution, the impact is clinically negligible (<7% reduction in absorption, per Clinical Pharmacokinetics 2023). Conversely, concurrent use of levodopa (for Parkinson’s disease) is cautioned: high-dose iron may impair intestinal decarboxylation of levodopa, reducing CNS bioavailability. No clinically relevant interactions were observed with levothyroxine in VALOR substudy participants, though standard 4-hour separation remains best practice.

Valdis is not recommended for individuals with untreated hereditary hemochromatosis (HFE C282Y homozygosity), as confirmed by genetic testing or elevated serum ferritin (>300 ng/mL) with transferrin saturation >45%. It is also contraindicated in those with documented allergy to glycine, cobalamins, or any inactive ingredient (microcrystalline cellulose, croscarmellose sodium, magnesium stearate, silicon dioxide).

Real-World Implementation: Case Examples and Counseling Points

In clinical practice, Valdis has proven especially valuable for three patient profiles: (1) those with prior pregnancy-related iron deficiency anemia and GI intolerance, (2) individuals with confirmed MTHFR variants seeking active folate, and (3) patients with elevated baseline hepcidin (>25 ng/mL) suggesting functional iron deficiency despite normal ferritin. A case series from Oregon Health & Science University tracked 87 patients switched to Valdis at 12 weeks’ gestation after failing ferrous sulfate. At 28 weeks, 94% maintained Hb ≥11.0 g/dL without transfusion, and 81% reported resolution of chronic constipation—compared to 43% in historical controls managed with stool softeners and dose reduction.

When counseling patients, doulas and clinicians emphasize evidence-based framing: 'This isn’t just “more iron”—it’s iron your body can actually absorb and use without upsetting your stomach. The folate is already in the form your cells need, so your baby gets full support for brain development from day one.' Language matters: avoid terms like 'enhanced' or 'superior' unless paired with cited data. Instead, say: 'In clinical trials, people taking Valdis absorbed nearly 2.5 times more iron and were nearly twice as likely to stay on their supplement through pregnancy.'

Patients frequently ask whether Valdis replaces DHA. It does not—it contains no omega-3s. Therefore, concurrent DHA supplementation (at least 200 mg/day, e.g., Nordic Naturals Prenatal DHA) remains essential. Valdis also contains no calcium, so patients requiring calcium for hypertension prevention or bone health should continue separate supplementation—ideally timed separately to avoid interference.

Monitoring recommendations align with ACOG standards: complete blood count and ferritin at initial visit, then repeat at 24–28 weeks if risk factors exist. For Valdis users, ferritin recheck is optional at 24 weeks unless symptoms recur; however, RBC folate testing is not routinely needed given the high-dose L-methylfolate formulation and robust cord blood data showing consistent elevation.

Finally, while Valdis improves iron and folate metrics, it does not replace comprehensive prenatal care. Nutrition assessment, mental health screening, social determinants evaluation, and birth planning remain foundational. As one certified doula in Austin, TX, shared in a 2023 NAPS survey: 'Valdis helps me support clients who’ve struggled with fatigue and anxiety linked to undiagnosed iron deficiency—but it’s one tool among many. We still prioritize food-first iron (lentils, spinach, beef liver), vitamin C pairing, and rest.’

Valdis represents a meaningful evolution in prenatal nutrition science—not by introducing novel nutrients, but by optimizing delivery, activation, and tolerability of well-established essentials. Its adoption reflects growing recognition that adherence is a clinical outcome, not just a behavioral footnote. When 86% of patients can take their iron daily without side effects, we shift from managing deficiency to proactively nurturing resilience—maternally, placentally, and neurodevelopmentally.

For providers, prescribing Valdis signals attentiveness to pharmacogenomics, gastrointestinal physiology, and real-world adherence barriers. For patients, it offers tangible relief—less nausea, steadier energy, and confidence that every tablet contributes meaningfully to their baby’s foundation. As research continues—including an ongoing NIH-funded study on Valdis and infant language acquisition at 18 months—the emphasis remains clear: precision matters, especially when building human life.

Valdis is manufactured by MedPharm Therapeutics, headquartered in Cambridge, MA. Lot-specific stability testing confirms potency retention ≥98.5% through 36 months when stored at 25°C/60% RH. Each tablet is imprinted with ‘VAL 27’ and bears NDC 70518-027-30. Full prescribing information is available at valdis.com/hcp.

Disclosure: MedPharm Therapeutics provided unrestricted educational grants to the National Association of Prenatal Services (NAPS) in 2023 for clinician training modules on iron metabolism in pregnancy. The author has no financial relationship with MedPharm Therapeutics or its affiliates.